Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy.

Endocrine-related cancer - 1 Nov 2024

Gujarathi Rushabh, Abou Azar Sara, Tobias Joseph, Polite Blase N, Setia Namrata, Feinberg Nicholas, Appelbaum Daniel E, Keutgen Xavier M, Liao Chih-Yi

Abstract excerpt

Pre-clinical data suggest that mutations in the MEN1, DAXX, and/or ATRX genes may potentially increase radiation efficacy in cancer cells. Herein, we explore the association between response to peptide receptor radionuclide therapy (PRRT) and those mutations in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). We analyzed tissue-based next generation sequencing (NGS) assay results and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Co-Repressor Proteins
Share to Intestinal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Chaperones

Share to Neuroendocrine Tumors

Share to Pancreatic Neoplasms

Share to Progression-Free Survival

Share to Receptors, Peptide

Share to X-linked Nuclear Protein

Source

Identifiers

PMID: 39093924
DOI: 10.1530/ERC-24-0065

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy.PMID 39093924Read ↗

Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy.Semantic proximity Read ↗

Whole genome and exome sequencing of pancreatic neuroendocrine tumour to investigate PRRT response.Semantic proximity Read ↗

DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivoSemantic proximity Read ↗

Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Advanced Neuroendocrine Tumours (NETs) in a Limited Resource EnvironmentSemantic proximity Read ↗

Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine TumorsSemantic proximity Read ↗

Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.Semantic proximity Read ↗

DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumorsSemantic proximity Read ↗

Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour sizeSemantic proximity Read ↗

Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.Semantic proximity Read ↗

Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?Semantic proximity Read ↗

Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted TherapySemantic proximity Read ↗

Understanding the Radiobiological Mechanisms Induced by 177Lu-DOTATATE in Comparison to External Beam Radiation TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.